Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117084 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL15866526 | 1.00 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29443698 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29709949 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29359628 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL3663656 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL29636980 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL121431 | 0.93 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL15866535 | 0.92 | ELANE (0.85) | ELANECYP3A4CYP2C9 | |
| SCHEMBL121570 | 0.91 | ELANE (0.87) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417112-B1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER IP GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20120094968-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTTTUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2417112-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115548-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094968-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTTTUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | STS, SQOR, TST | ELANE 2343/4885CYP3A4 1774/4885CYP2C9 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.